Epigenetic and sex differences in opioid use disorder in chronic pain: A real-world study linked with OPRM1 DNA methylation.
DNA methylation
OPRM1 gene
chronic pain
epigenetics
opioid use disorder
pharmacogenetics
sex differences
Journal
Addiction biology
ISSN: 1369-1600
Titre abrégé: Addict Biol
Pays: United States
ID NLM: 9604935
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
revised:
24
05
2024
received:
05
02
2024
accepted:
04
06
2024
medline:
1
7
2024
pubmed:
1
7
2024
entrez:
1
7
2024
Statut:
ppublish
Résumé
Opioid use disorder (OUD) is a multifaceted condition influenced by sex, genetic and environmental factors that could be linked with epigenetic changes. Understanding how these factors interact is crucial to understand and address the development and progression of this disorder. Our aim was to elucidate different potential epigenetic and genetic mechanisms between women and men that correlate with OUD under real-world pain unit conditions. Associations between analgesic response and the DNA methylation level of the opioid mu receptor (OPRM1) gene (CpG sites 1-5 selected in the promoter region) were evaluated in 345 long opioid-treated chronic non cancer pain: cases with OUD (n = 67) and controls (without OUD, n = 278). Cases showed younger ages, low employment status and quality of life, but higher morphine equivalent daily dose and psychotropic use, compared to the controls. The patients with OUD showed a significant decrease in OPRM1 DNA methylation, which correlated with clinical outcomes like pain relief, depression and different adverse events. Significant differences were found at the five CpG sites studied for men, and exclusively in women for CpG site 3, in relation to OUD diagnosis. These findings support the importance of epigenetics and sex as biological variables to be considered toward efficient OUD understanding and therapy development.
Substances chimiques
Receptors, Opioid, mu
0
OPRM1 protein, human
0
Analgesics, Opioid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13422Subventions
Organisme : Carlos III Health Institute
ID : ICI20/00146
Informations de copyright
© 2024 The Author(s). Addiction Biology published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
Références
Volkow N, Benveniste H, McLellan AT. Use and misuse of opioids in chronic pain. Annu Rev Med. 2018;69:451‐465. doi:10.1146/annurev‐med‐011817‐044739
Huhn AS, Berry MS, Dunn KE. Review: sex‐based differences in treatment outcomes for persons with opioid use disorder. Am J Addict. 2019;28(4):246‐261. doi:10.1111/ajad.12921
Serdarevic M, Striley CW, Cottler LB. Sex differences in prescription opioid use. Curr Opin Psychiatry. 2017;30(4):238‐246. doi:10.1097/YCO.0000000000000337
Santos‐Toscano R, Arevalo MA, Garcia‐Segura LM, Grassi D, Lagunas N. Interaction of gonadal hormones, dopaminergic system, and epigenetic regulation in the generation of sex differences in substance use disorders: a systematic review. Front Neuroendocrinol. 2023;71:101085. doi:10.1016/j.yfrne.2023.101085
Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287. doi:10.1016/j.ejpain.2005.06.009
McClelland LE, McCubbin JA. Social influence and pain response in women and men. J Behav Med. 2008;31(5):413‐420. doi:10.1007/s10865‐008‐9163‐6
Todd A, McNamara CL, Balaj M, et al. The European epidemic: pain prevalence and socioeconomic inequalities in pain across 19 European countries. Eur J Pain. 2019;23(8):1425‐1436. doi:10.1002/ejp.1409
Gerra MC, Dallabona C, Arendt‐Nielsen L. Epigenetic alterations in prescription opioid misuse: new strategies for precision pain management. Genes (Basel). 2021;12(8):1226. doi:10.3390/genes12081226
Becker JB, Mazure CM. The federal plan for health science and technology's response to the opioid crisis: understanding sex and gender differences as part of the solution is overlooked. Biol Sex Differ. 2019;10(1):3. doi:10.1186/s13293‐018‐0215‐5
Agulló L, Muriel J, Margarit C, et al. Sex differences in opioid response linked to OPRM1 and COMT genes DNA methylation/genotypes changes in patients with chronic pain. J Clin Med. 2023;12(10):3449. doi:10.3390/jcm12103449
Anderson EM, Penrod RD, Barry SM, Hughes BW, Taniguchi M, Cowan CW. It is a complex issue: emerging connections between epigenetic regulators in drug addiction. Eur J Neurosci. 2019;50(3):2477‐2491. doi:10.1111/ejn.14170
Owusu Obeng A, Hamadeh I, Smith M. Review of opioid pharmacogenetics and considerations for pain management. Pharmacotherapy. 2017;37(9):1105‐1121. doi:10.1002/phar.1986
Mague SD, Isiegas C, Huang P, Liu‐Chen LY, Lerman C, Blendy JA. Mouse model of OPRM1 (A118G) polymorphism has sex‐specific effects on drug‐mediated behavior. Proc Natl Acad Sci U S a. 2009;106(26):10847‐10852. doi:10.1073/pnas.0901800106
Pisanu C, Franconi F, Gessa GL, et al. Sex differences in the response to opioids for pain relief: a systematic review and meta‐analysis. Pharmacol Res. 2019;148:104447. doi:10.1016/j.phrs.2019.104447
Oertel BG, Doehring A, Roskam B, et al. Genetic‐epigenetic interaction modulates μ‐opioid receptor regulation. Hum Mol Genet. 2012;21(21):4751‐4760. doi:10.1093/hmg/dds314
Muriel J, Margarit C, Planelles B, et al. OPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patients. Ann N Y Acad Sci. 2018;1425(1):82‐93. doi:10.1111/nyas.13735
Zhang Y, Picetti R, Butelman ER, Ho A, Blendy JA, Kreek MJ. Mouse model of the OPRM1 (A118G) polymorphism: differential heroin self‐administration behavior compared with wild‐type mice. Neuropsychopharmacology. 2015;40(5):1091‐1100. doi:10.1038/npp.2014.286
Muriel J, Margarit C, Barrachina J, et al. Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients. Basic Clin Pharmacol Toxicol. 2019;124(4):439‐448. doi:10.1111/bcpt.13155
Swiergiel AH, Juszczak GR, Stankiewicz AM. Genetic and epigenetic mechanisms linking pain and psychiatric disorders. Mod Trends Pharmacopsychiatry. 2015;30:120‐137. doi:10.1159/000435937
Chmielowiec K, Chmielowiec J, Masiak J, et al. Associations between the COMT rs4680 gene polymorphism and personality dimensions and anxiety in patients with a diagnosis of other stimulants dependence. Genes (Basel). 2022;13(10):1768. doi:10.3390/genes13101768
Polli A, Ickmans K, Godderis L, Nijs J. When environment meets genetics: a clinical review of the epigenetics of pain, psychological factors, and physical activity. Arch Phys Med Rehabil. 2019;100(6):1153‐1161. doi:10.1016/j.apmr.2018.09.118
Browne CJ, Godino A, Salery M, Nestler EJ. Epigenetic mechanisms of opioid addiction. Biol Psychiatry. 2020;87(1):22‐33. doi:10.1016/j.biopsych.2019.06.027
Kubota T, Miyake K, Hirasawa T. Epigenetic understanding of gene‐environment interactions in psychiatric disorders: a new concept of clinical genetics. Clin Epigenetics. 2012;4(1):1. doi:10.1186/1868‐7083‐4‐1
Crist RC, Reiner BC, Berrettini WH. A review of opioid addiction genetics. Curr Opin Psychol. 2019;27:31‐35. doi:10.1016/j.copsyc.2018.07.014
Goldenberg DL, Clauw DJ, Palmer RE, Clair AG. Opioid use in fibromyalgia: a cautionary tale. Mayo Clin Proc. 2016;91(5):640‐648. doi:10.1016/j.mayocp.2016.02.002
McNicol E, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013;8. doi:10.1002/14651858.CD006146.pub2
Lee CWS, Ho IK. Sex differences in opioid analgesia and addiction: interactions among opioid receptors and estrogen receptors. Mol Pain. 2013;9(1):45. doi:10.1186/1744‐8069‐9‐45
Musey PI, Linnstaedt SD, Platts‐Mills TF, et al. Gender differences in acute and chronic pain in the emergency department: results of the 2014 academic emergency medicine consensus conference pain section. Acad Emerg Med. 2014;21(12):1421‐1430. doi:10.1111/acem.12529
Yoshida K, Nishizawa D, Ide S, Ichinohe T, Fukuda KI, Ikeda K. A pharmacogenetics approach to pain management. Neuropsychopharmacol Rep. 2018;38(1):2‐8. doi:10.1002/npr2.12003
Manubay J, Davidson J, Vosburg S, Jones J, Comer S, Sullivan M. Sex differences among opioid‐abusing patients with chronic pain in a clinical trial. J Addict Med. 2015;9(1):46‐52. doi:10.1097/ADM.0000000000000086
Gapp K, Jawaid A, Sarkies P, et al. Implication of sperm RNAs in transgenerational inheritance of the effects of early trauma in mice. Nat Neurosci. 2014;17(5):667‐669. doi:10.1038/nn.3695
Mogil JS, Chesler EJ, Wilson SG, Juraska JM, Sternberg WF. Sex differences in thermal nociception and morphine antinociception in rodents depend on genotype. Neurosci Biobehav Rev. 2000;24(3):375‐389. doi:10.1016/S0149‐7634(00)00015‐4
Bernal SA, Morgan MM, Craft RM. PAG mu opioid receptor activation underlies sex differences in morphine antinociception. Behav Brain Res. 2007;177(1):126‐133. doi:10.1016/j.bbr.2006.10.028
Liu A, Zhang H, Qin F, et al. Sex associated differential expressions of the alternatively spliced variants mRNA of OPRM1 in brain regions of C57BL/6 mouse. Cell Physiol Biochem. 2018;50(4):1441‐1459. doi:10.1159/000494644
Bai X, Zhang X, Li Y, Lu L, Li B, He X. Sex differences in peripheral mu‐opioid receptor mediated analgesia in rat orofacial persistent pain model. PLoS ONE. 2015;10(3):e0122924. doi:10.1371/journal.pone.0122924
Verzillo V, Madia PA, Liu NJ, Chakrabarti S, Gintzler AR. Mu‐opioid receptor splice variants: sex‐dependent regulation by chronic morphine. J Neurochem. 2014;130(6):790‐796. doi:10.1111/jnc.12768
Loyd DR, Wang X, Murphy AZ. Sex differences in micro‐opioid receptor expression in the rat midbrain periaqueductal gray are essential for eliciting sex differences in morphine analgesia. J Neurosci. 2008;28(52):14007‐14017. doi:10.1523/JNEUROSCI.4123‐08.2008
Zhang X, Zhang Y, Asgar J, et al. Sex differences in μ‐opioid receptor expression in trigeminal ganglia under a myositis condition in rats. Eur J Pain. 2014;18(2):151‐161. doi:10.1002/j.1532‐2149.2013.00352.x
Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long‐term opioid therapy for chronic pain: a systematic review for a national institutes of health pathways to prevention workshop. Ann Intern Med. 2015;162(4):276‐286. doi:10.7326/M14‐2559
Escorial M, Muriel J, Agulló L, et al. Clinical prediction of opioid use disorder in chronic pain patients: a cohort‐retrospective study with a pharmacogenetic approach. Minerva Anestesiol. 2024;90(5):386‐396. doi:10.23736/S0375‐9393.24.17864‐9
Park JY, Wu LT. Sources of misused prescription opioids and their association with prescription opioid use disorder in the United States: sex and age differences. Subst Use Misuse. 2020;55(6):928‐936. doi:10.1080/10826084.2020.1713818
Dahlman D, Ohlsson H, Edwards AC, Sundquist J, Håkansson A, Sundquist K. Socioeconomic correlates of incident and fatal opioid overdose among Swedish people with opioid use disorder. Subst Abuse Treat Prev Policy. 2021;16(1):73. doi:10.1186/s13011‐021‐00409‐3
Thielke SM, Turner JA, Shortreed SM, et al. Do patient‐perceived pros and cons of opioids predict sustained higher‐dose use? Clin J Pain. 2014;30(2):93‐101. doi:10.1097/AJP.0b013e31828e361b
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM‐5™. 5th ed; 2013.